Keyword price-impact finder

How stocks move after “FDA approval” headlines

Biotech and pharma headlines announcing an FDA approval. Every single-ticker headline on the Quantisnow wire containing “FDA approval” in the last 12 months, measured to the next close.

After 242 headlines containing “FDA approval” (209 distinct stock-sessions), the stock moved +1.01% on average by the next close (median +0.03%), and closed higher 51% of the time.

Average move
+1.01%
Next close vs prior close
Median move
+0.03%
Closed higher
51%
Share of stock-sessions
Avg absolute move
3.79%
Volatility around the headline
Sample
209
Stock-sessions from 242 headlines
Average vs SPY
+1.07%
Move minus SPY same session
5-session average
+0.38%
Median -0.01%, 195 headlines

How often it shows up

Per day
0.66
Per month
20.2
Per year
242
015304560Nov 25: Headlines 0Nov 25Dec 25: Headlines 19Jan 26: Headlines 8Jan 26Feb 26: Headlines 9Mar 26: Headlines 18Mar 26Apr 26: Headlines 11May 26: Headlines 22May 26Jun 26: Headlines 22Jul 26: Headlines 17Jul 26Aug 26: Headlines 20Sep 26: Headlines 21Sep 26Oct 26: Headlines 21Nov 26: Headlines 54Nov 26
Single-ticker headlines containing “FDA approval” per month. The latest month is to date.

Distribution of next-close moves

Recent headlines

Date (UTC)TickerHeadlineNext close5 sessions
2026-11-19 13:02JNJJohnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication-2.04%-
2026-11-19 12:23REGNFDA Approval for LIVSAYIS issued to REGENERON PHARMACEUTICALS-2.35%-
2026-11-19 12:00ALNYAlnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years-1.06%-
2026-11-19 11:26SNYFDA Approval for INFILBRAY issued to GENZYME CORP A SANOFI CO-2.25%-
2026-11-18 09:48AMRXFDA Approval for DEXMETHYLPHENIDATE HYDROCHLORIDE issued to IMPAX LABS INC+3.60%-
2026-11-18 09:48VTRSFDA Approval for VORICONAZOLE issued to MYLAN PHARMS INC-0.83%-
2026-11-17 19:52LLYFDA Approval for RETEVMO issued to ELI LILLY AND CO-1.13%-
2026-11-17 19:52LLYFDA Approval for RETEVMO issued to ELI LILLY AND CO-1.13%-
2026-11-17 09:51AMRXFDA Approval for KETAMINE HYDROCHLORIDE issued to AMNEAL-0.52%-
2026-11-17 09:51VTRSFDA Approval for GLATIRAMER ACETATE issued to MYLAN-1.40%-
2026-11-17 09:51VTRSFDA Approval for GLATIRAMER ACETATE issued to MYLAN-1.40%-
2026-11-17 05:49TEVAFDA Approval for AMIFAMPRIDINE PHOSPHATE issued to TEVA PHARMS INC+0.12%-
2026-11-16 19:49TEVAFDA Approval for IGALMI issued to TEVA-4.34%-
2026-11-16 19:49BIIBFDA Approval for ZURZUVAE issued to BIOGEN-0.69%-
2026-11-16 11:47TEVAFDA Approval for LAMOTRIGINE issued to ACTAVIS ELIZABETH-4.34%-
2026-11-16 11:47CYTKFDA Approval for MYQORZO issued to CYTOKINETICS-5.27%-
2026-11-16 11:47TEVAFDA Approval for LAMOTRIGINE issued to ACTAVIS ELIZABETH-4.34%-
2026-11-16 11:47ALKSFDA Approval for LUMRYZ issued to ALKERMES INC-1.06%-
2026-11-13 19:30AZNFDA Approval for KLYGEFA issued to ALEXION PHARM+0.04%-4.86%
2026-11-13 13:27JNJFDA Approval for LAZCLUZE issued to JANSSEN BIOTECH+0.79%-5.78%
2026-11-12 21:01NSPRInspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures-16.78%-19.83%
2026-11-12 14:21SNYFDA Approval for CHILDREN'S ALLEGRA ALLERGY issued to CHATTEM SANOFI+0.06%-2.70%
2026-11-12 14:21SNYFDA Approval for ALLEGRA HIVES issued to CHATTEM SANOFI+0.06%-2.70%
2026-11-12 14:21RIGLFDA Approval for GAVRETO issued to RIGEL PHARMS+2.63%-4.47%
2026-11-12 14:21SNYFDA Approval for ALLEGRA ALLERGY issued to CHATTEM SANOFI+0.06%-2.70%

Methodology